Real time imaging of tolerance induction by mucosal DCs

粘膜 DC 耐受诱导的实时成像

基本信息

  • 批准号:
    8142934
  • 负责人:
  • 金额:
    $ 23.76万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-09-15 至 2013-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Dendiritc cells (DCs) play a vital role in initiating protective immune responses against pathogens, but they are also implicated in the induction and maintenance of tolerance. These diverse functions of DCs are most apparent within the gastrointestinal tract where hypo-responsiveness to commensal flora and food antigens needs to be maintained, while generating efficient immune responses against pathogens. However the mechanisms by which these functions coexist are currently unclear. Resident fractalkine receptor (CX3CR1+) expressing DCs in the mucosal tract have recently has been shown to be involved in directly sampling the contents of the intestinal lumen through extension of transepithelial dendrite and express a tolerogenic phenotype under steady state conditions. However, it is not known if these DCs are directly involved in inducing T cell tolerance to the luminal antigens they sample. The inability to mimic the complex milieu that these DCs encounter within the mucosal tract, in vitro to study their function, makes it difficult to address many of these questions by conventional techniques. This proposal utilizes deep tissue imaging by multiphoton microscopy to directly assess the function of CX3CR1+ DCs in situ. The antigen presentation by fluorescently tagged DCs and antigen-specific T cells following infection with recombinant antigen-expressing bacteria that model commensal flora (E.coli-OVA) will be used to determine if CX3CR1+ DCs are directly involved in the induction of tolerogenic T cell responses. A second objective of this proposal is to determine if the function of CX3CR1+ DCs is altered during an inflammatory response induced following pathogen infection. A co-infection model with pathogenic S. typhimurium and E.coli Ova where ovalbumin expression is limited to E.coli will be used to address this question. Such a model will allow tracking of antigen specific responses to a "commensal- like" antigen during inflammatory conditions. As CX3CR1+ DCs are continually sampling commensal bacteria and food antigens, plasticity in their function during an inflammatory response could play a role in the breakdown of oral tolerance. PUBLIC HEALTH RELEVANCE: The current studies will reveal if the resident CX3CR1+ DC form a functionally important arm of the mucosal innate immune cell machinery that maintains oral tolerance, which is vital for preventing adverse immune responses against food antigens and commensals. In addition, we will determine if plasticity of the CX3CR1+ DC functional response contributes to the breakdown of oral tolerance under inflammatory conditions, potentially identifying them as targets for future therapeutics to treat food allergies and inflammatory bowel diseases.
描述(由申请人提供):树突状细胞(DC)在启动针对病原体的保护性免疫应答中起重要作用,但它们也涉及耐受性的诱导和维持。DC的这些不同功能在胃肠道内最明显,在胃肠道中需要维持对肠道植物群和食物抗原的低应答性,同时产生针对病原体的有效免疫应答。然而,这些功能共存的机制目前尚不清楚。在粘膜道中表达驻留的Fractalkine受体(CX 3CR 1+)的DC最近已被证明通过跨上皮树突的延伸参与肠腔内容物的直接取样,并且在稳态条件下表达致耐受性表型。然而,尚不清楚这些DC是否直接参与诱导T细胞对它们采样的管腔抗原的耐受。不能模拟这些DC在粘膜道内遇到的复杂环境,在体外研究它们的功能,使得难以通过常规技术解决许多这些问题。该建议利用多光子显微镜的深层组织成像来直接评估原位CX 3CR 1 + DC的功能。在用模拟肠道植物群的重组抗原表达细菌(大肠杆菌-OVA)感染后,荧光标记的DC和抗原特异性T细胞的抗原呈递将用于确定CX 3CR 1 + DC是否直接参与诱导致耐受性T细胞应答。该建议的第二个目的是确定在病原体感染后诱导的炎症反应期间CX 3CR 1 + DC的功能是否改变。建立了致病性S.鼠伤寒沙门氏菌和大肠杆菌Ova,其中卵清蛋白表达限于大肠杆菌,将用于解决这个问题。这样的模型将允许在炎性病症期间追踪对“类脑膜炎”抗原的抗原特异性应答。由于CX 3CR 1 + DCs持续采样肠道细菌和食物抗原,因此在炎症反应期间其功能的可塑性可能在口服耐受性的破坏中发挥作用。 公共卫生相关性:目前的研究将揭示常驻CX 3CR 1 + DC是否形成维持口服耐受性的粘膜先天免疫细胞机制的功能重要臂,这对于预防针对食物抗原和唾液的不良免疫应答至关重要。此外,我们将确定CX 3CR 1 + DC功能反应的可塑性是否有助于炎症条件下口服耐受的破坏,可能将其确定为未来治疗食物过敏和炎症性肠病的靶点。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Improved delivery of the OVA-CD4 peptide to T helper cells by polymeric surface display on Salmonella.
  • DOI:
    10.1186/1475-2859-13-80
  • 发表时间:
    2014-06-04
  • 期刊:
  • 影响因子:
    6.4
  • 作者:
    Zhang J;De Masi L;John B;Chen W;Schifferli DM
  • 通讯作者:
    Schifferli DM
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Beena John其他文献

Beena John的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Beena John', 18)}}的其他基金

Real time imaging of tolerance induction by mucosal DCs
粘膜 DC 耐受诱导的实时成像
  • 批准号:
    7962037
  • 财政年份:
    2010
  • 资助金额:
    $ 23.76万
  • 项目类别:

相似海外基金

Defining MHC class I restricted antigen presentation to CD8 T cells in experimental AD and Tauopathy - Supplement
定义实验性 AD 和 Tau 病中 MHC I 类限制性抗原呈递至 CD8 T 细胞 - 补充
  • 批准号:
    10836880
  • 财政年份:
    2023
  • 资助金额:
    $ 23.76万
  • 项目类别:
Targeting MAL2-mediated endocytosis to enhance tumor cell antigen presentation
靶向 MAL2 介导的内吞作用以增强肿瘤细胞抗原呈递
  • 批准号:
    10734324
  • 财政年份:
    2023
  • 资助金额:
    $ 23.76万
  • 项目类别:
Antigen presentation to the adaptive immune system in the choroid contributes to ocular autoimmune disease
脉络膜中的适应性免疫系统的抗原呈递导致眼部自身免疫性疾病
  • 批准号:
    10740465
  • 财政年份:
    2023
  • 资助金额:
    $ 23.76万
  • 项目类别:
Investigation of Target Protein Degradation and Its Effect on Enhancing Cancer-Specific Antigen Presentation by Quantitative Mass Spectrometry
通过定量质谱研究靶蛋白降解及其对增强癌症特异性抗原呈递的影响
  • 批准号:
    23K04971
  • 财政年份:
    2023
  • 资助金额:
    $ 23.76万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Promoting cancer cells' antigen presentation for serving as better targets for T cell immunotherapy
促进癌细胞的抗原呈递,作为 T 细胞免疫治疗的更好靶点
  • 批准号:
    2885451
  • 财政年份:
    2023
  • 资助金额:
    $ 23.76万
  • 项目类别:
    Studentship
Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy
结直肠癌免疫治疗中靶向免疫蛋白酶体介导的抗原呈递
  • 批准号:
    10385926
  • 财政年份:
    2022
  • 资助金额:
    $ 23.76万
  • 项目类别:
Lipid Antigen Presentation as a Driver of T2D Inflammation
脂质抗原呈递作为 T2D 炎症的驱动因素
  • 批准号:
    10509043
  • 财政年份:
    2022
  • 资助金额:
    $ 23.76万
  • 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
  • 批准号:
    10704008
  • 财政年份:
    2022
  • 资助金额:
    $ 23.76万
  • 项目类别:
Sex Differences in lipid antigen presentation, impact of lipid antigen presentation on peripheral lipid metabolism
脂质抗原呈递的性别差异,脂质抗原呈递对外周脂质代谢的影响
  • 批准号:
    10818273
  • 财政年份:
    2022
  • 资助金额:
    $ 23.76万
  • 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
  • 批准号:
    10349397
  • 财政年份:
    2022
  • 资助金额:
    $ 23.76万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了